• Profile

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA)

The Lancet: Gastroenterology & Hepatology May 05, 2022

Why this study matters

As new pharmaceuticals are approved for the treatment of inflammatory bowel disease, and UC in particular, head-to-head comparative studies are essential to determine safety, and to further evaluate clinically meaningful measures of efficacy.

Study design

A phase 3 study (GARDENIA) was conducted at 14 centers involving 397 patients with moderate-to-severe UC. 

The patients were randomized to the etrolizumab (n=199) or infliximab (n=198) group; 95 and 103 patients in the etrolizumab and infliximab groups completed the study, respectively.  Etrolizumab (105 mg q4w sc) or infliximab (5 mg at weeks 0, 2, and 6, then q8w x 52w iv) was administered. 

The outcomes were clinical response at 10 weeks and clinical remission at 54 weeks.

Results and conclusion

Thirty-seven (18.6%) and 39 (19.7%) of patients in the etrolizumab and infliximab groups met the primary endpoint at week 54.  Adverse events were similar in both groups (77% and 76%, respectively).

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen